Arch Therapeutics, Inc. (ARTH)
USD 0.16
(-10.93%)
USD 0.16
(-10.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.95 Million USD | -24.79% |
| 2022 | 2.6 Million USD | -29.18% |
| 2021 | 3.67 Million USD | 70.92% |
| 2020 | 2.15 Million USD | -25.88% |
| 2019 | 2.9 Million USD | -40.04% |
| 2018 | 4.83 Million USD | -20.53% |
| 2017 | 6.09 Million USD | 18.39% |
| 2016 | 5.14 Million USD | 28.51% |
| 2015 | 4 Million USD | 356.45% |
| 2014 | 876.99 Thousand USD | -44.75% |
| 2013 | 1.58 Million USD | 33544.17% |
| 2012 | 4718.00 USD | -73.82% |
| 2011 | 18.02 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.82 Million USD | -6.96% |
| 2024 Q3 | 1.39 Million USD | -9.25% |
| 2024 Q2 | 1.54 Million USD | -15.47% |
| 2023 Q1 | 1.71 Million USD | -34.09% |
| 2023 Q4 | 1.95 Million USD | 25.18% |
| 2023 FY | 1.95 Million USD | -24.79% |
| 2023 Q3 | 1.56 Million USD | -1.79% |
| 2023 Q2 | 1.59 Million USD | -7.19% |
| 2022 Q1 | 2.54 Million USD | -30.81% |
| 2022 FY | 2.6 Million USD | -29.18% |
| 2022 Q4 | 2.6 Million USD | 65.52% |
| 2022 Q2 | 1.43 Million USD | -43.41% |
| 2022 Q3 | 1.57 Million USD | 9.29% |
| 2021 FY | 3.67 Million USD | 70.92% |
| 2021 Q1 | 2.09 Million USD | -2.37% |
| 2021 Q2 | 6.85 Million USD | 226.33% |
| 2021 Q3 | 4.99 Million USD | -27.1% |
| 2021 Q4 | 3.67 Million USD | -26.41% |
| 2020 Q4 | 2.15 Million USD | -32.06% |
| 2020 FY | 2.15 Million USD | -25.88% |
| 2020 Q1 | 3.56 Million USD | 22.88% |
| 2020 Q2 | 2.89 Million USD | -18.83% |
| 2020 Q3 | 3.16 Million USD | 9.38% |
| 2019 Q3 | 3.79 Million USD | 56.22% |
| 2019 Q2 | 2.42 Million USD | -33.28% |
| 2019 Q1 | 3.63 Million USD | -24.86% |
| 2019 Q4 | 2.9 Million USD | -23.44% |
| 2019 FY | 2.9 Million USD | -40.04% |
| 2018 Q4 | 4.83 Million USD | -26.66% |
| 2018 Q2 | 3.46 Million USD | -31.26% |
| 2018 Q1 | 5.04 Million USD | -17.19% |
| 2018 Q3 | 6.59 Million USD | 90.37% |
| 2018 FY | 4.83 Million USD | -20.53% |
| 2017 Q4 | 6.09 Million USD | -3.69% |
| 2017 FY | 6.09 Million USD | 18.39% |
| 2017 Q3 | 6.32 Million USD | -16.57% |
| 2017 Q2 | 7.57 Million USD | 94.24% |
| 2017 Q1 | 3.9 Million USD | -24.15% |
| 2016 FY | 5.14 Million USD | 28.51% |
| 2016 Q4 | 5.14 Million USD | -12.85% |
| 2016 Q1 | 2.86 Million USD | -28.34% |
| 2016 Q3 | 5.9 Million USD | 235.52% |
| 2016 Q2 | 1.75 Million USD | -38.66% |
| 2015 Q3 | 3.31 Million USD | 447.46% |
| 2015 Q1 | 824.44 Thousand USD | -5.99% |
| 2015 FY | 4 Million USD | 356.45% |
| 2015 Q4 | 4 Million USD | 20.65% |
| 2015 Q2 | 606.04 Thousand USD | -26.49% |
| 2014 Q4 | 876.99 Thousand USD | -52.2% |
| 2014 FY | 876.99 Thousand USD | -44.75% |
| 2014 Q3 | 1.83 Million USD | -31.35% |
| 2014 Q2 | 2.67 Million USD | 168.49% |
| 2014 Q1 | 995.41 Thousand USD | -37.29% |
| 2013 Q1 | 3453.00 USD | -26.81% |
| 2013 Q3 | 477.55 Thousand USD | 23048.38% |
| 2013 Q4 | 1.58 Million USD | 232.39% |
| 2013 Q2 | 2063.00 USD | -40.25% |
| 2013 FY | 1.58 Million USD | 33544.17% |
| 2012 FY | 4718.00 USD | -73.82% |
| 2012 Q1 | 10 Thousand USD | -44.52% |
| 2012 Q3 | 20.3 Thousand USD | 302.26% |
| 2012 Q4 | 4718.00 USD | -76.77% |
| 2012 Q2 | 5048.00 USD | -49.52% |
| 2011 FY | 18.02 Thousand USD | 0.0% |
| 2011 Q4 | 18.02 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -84670.087% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 81.446% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -254.667% |
| Rebus Holdings, Inc. | 5000.00 USD | -39063.78% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.496% |
| Qrons Inc. | 420.00 USD | -466135.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -154.098% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 92.992% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -307.483% |
| Skye Bioscience, Inc. | 11.94 Million USD | 83.6% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 94.959% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 72.877% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2464.619% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.173% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -36.742% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2605.989% |
| Mesoblast Limited | 667.9 Million USD | 99.707% |
| Marizyme, Inc. | 22.01 Million USD | 91.105% |
| Genus plc | 1.02 Billion USD | 99.81% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -44.159% |
| Pharming Group N.V. | 462.85 Million USD | 99.577% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 40.894% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -292.392% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -212.311% |
| ContraFect Corporation | 20.67 Million USD | 90.531% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -401.629% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -412.378% |
| IMV Inc. | 31.33 Million USD | 93.751% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 52.769% |
| MultiCell Technologies, Inc. | 126.22 USD | -1551309.444% |
| ONE Bio Corp. | 70.08 Million USD | 97.206% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -108.387% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.476% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -353.585% |
| Q BioMed Inc. | 3.51 Million USD | 44.299% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 94.434% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -649.469% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2552.69% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.561% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -35.155% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 93.476% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 28.698% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -184.833% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 24.778% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1793.031% |
| Alpha Cognition Inc. | 2.45 Million USD | 20.145% |
| HST Global, Inc. | 1526.00 USD | -128221.691% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -98.204% |
| Halberd Corporation | 10.13 Thousand USD | -19228.684% |
| Enzolytics Inc. | 361.7 Million USD | 99.459% |
| Agentix Corp. | 261.39 Thousand USD | -649.139% |
| Resverlogix Corp. | 8.11 Million USD | 75.87% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -4.277% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.957% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 95.895% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -206.132% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8495.711% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 78.119% |
| AVAX Technologies, Inc. | 7.37 Million USD | 73.456% |
| Zenith Capital Corp. | 7410.00 USD | -26326.302% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.942% |
| Ember Therapeutics, Inc. | 184.00 USD | -1064133.152% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -508.5% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -649.219% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -111.021% |
| Kadimastem Ltd | 2.3 Million USD | 15.012% |
| Helix BioMedix, Inc. | 3.02 Million USD | 35.268% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 96.284% |
| BioStem Technologies, Inc. | 14.56 Million USD | 86.551% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3329.763% |
| LadRx Corporation | 2.3 Million USD | 15.152% |
| Cell Source, Inc. | 195.17 Thousand USD | -903.32% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -453.76% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -453.76% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3045.786% |
| Affymax, Inc. | 7.44 Million USD | 73.691% |
| Itoco Inc. | 1.4 Million USD | -39.863% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1947.094% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1747.348% |
| Mobile Lads Corp. | 52.00 USD | -3765648.077% |
| CytoDyn Inc. | 11.13 Million USD | 82.416% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1269.631% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -10851.84% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -407.999% |
| SYBLEU INC | 330.46 Thousand USD | -492.55% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -378.281% |
| International Stem Cell Corporation | 5.39 Million USD | 63.67% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1322.71% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 86.947% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 88.189% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2378.72% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -126.465% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 73.95% |
| Neutra Corp. | 2851.00 USD | -68584.286% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 93.957% |
| PureTech Health plc | 693.97 Million USD | 99.718% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 75.738% |
| IXICO plc | 15.84 Million USD | 87.641% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 76.356% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.105% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Cellectis S.A. | 333.99 Million USD | 99.414% |